These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 27521276)

  • 21. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
    Mediwake H; Morris K; Curley C; Butler J; Kennedy G
    Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Occurrence and prognostic relevance of CD30 expression in post-transplant lymphoproliferative disorders.
    Vase MØ; Maksten EF; Bendix K; Hamilton-Dutoit S; Andersen C; Møller MB; Sørensen SS; Jespersen B; Kampmann J; Søndergård E; Nielsen PS; D'amore F
    Leuk Lymphoma; 2015 Jun; 56(6):1677-85. PubMed ID: 25248878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.
    Wang W; Hu S; Lu X; Young KH; Medeiros LJ
    Am J Surg Pathol; 2015 Aug; 39(8):1132-9. PubMed ID: 25828391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD30 expression is common in mediastinal large B-cell lymphoma.
    Higgins JP; Warnke RA
    Am J Clin Pathol; 1999 Aug; 112(2):241-7. PubMed ID: 10439805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicentric MFI30 study: Standardization of flow cytometry analysis of CD30 expression in non-Hodgkin lymphoma.
    Debliquis A; Baseggio L; Bouyer S; Guy J; Garnache-Ottou F; Genevieve F; Mayeur-Rousse C; Letestu R; Chapuis N; Harrivel V; Bennani H; Lachot S; Loosveld M; Nicolino-Brunet C; Pérès M; Roussel M; Veyrat-Masson R; Jacob MC; Drenou B
    Cytometry B Clin Cytom; 2021 Jul; 100(4):488-496. PubMed ID: 32803917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sinusoidal CD30-positive large B-cell lymphoma: a morphologic mimic of anaplastic large cell lymphoma.
    Lai R; Medeiros LJ; Dabbagh L; Formenti KS; Coupland RW
    Mod Pathol; 2000 Mar; 13(3):223-8. PubMed ID: 10757332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T-cell leukemia 1 expression in nodal Epstein-Barr virus-negative diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma.
    Gualco G; Weiss LM; Barber GN; Bacchi CE
    Hum Pathol; 2010 Sep; 41(9):1238-44. PubMed ID: 20382409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. B-cell non-Hodgkin lymphomas in Uganda: an immunohistochemical appraisal on tissue microarray.
    Tumwine LK; Campidelli C; Righi S; Neda S; Byarugaba W; Pileri SA
    Hum Pathol; 2008 Jun; 39(6):817-23. PubMed ID: 18436278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
    Younes A; Bartlett NL; Leonard JP; Kennedy DA; Lynch CM; Sievers EL; Forero-Torres A
    N Engl J Med; 2010 Nov; 363(19):1812-21. PubMed ID: 21047225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct.
    Matolcsy A; Chadburn A; Knowles DM
    Am J Pathol; 1995 Jul; 147(1):207-16. PubMed ID: 7541611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma.
    Jagadeesh D; Horwitz S; Bartlett NL; Kim Y; Jacobsen E; Duvic M; Little M; Trepicchio W; Fenton K; Onsum M; Lisano J; Advani R
    Oncologist; 2022 Oct; 27(10):864-873. PubMed ID: 35948003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD30 Expression in Monomorphic Posttransplant Lymphoproliferative Disorder, Diffuse Large B-Cell Lymphoma Correlates With Greater Regulatory T-Cell Infiltration.
    Hartley C; Vaughan JW; Jarzembowski J; Kroft SH; Hosking P; Harrington AM; Olteanu H
    Am J Clin Pathol; 2017 Nov; 148(6):485-493. PubMed ID: 29126177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma.
    Bhatt S; Ashlock BM; Natkunam Y; Sujoy V; Chapman JR; Ramos JC; Mesri EA; Lossos IS
    Blood; 2013 Aug; 122(7):1233-42. PubMed ID: 23838350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis.
    Rassidakis GZ; Thomaides A; Atwell C; Ford R; Jones D; Claret FX; Medeiros LJ
    Mod Pathol; 2005 Oct; 18(10):1365-70. PubMed ID: 15920551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma.
    Xu J; Oki Y; Saksena A; Desai P; Lin P; Tang G; Yin CC; You MJ; Thakral B; Medeiros LJ; Li S
    Hum Pathol; 2017 Feb; 60():160-166. PubMed ID: 27816715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relation of CD30 expression to survival and morphology in large cell B cell lymphomas.
    Noorduyn LA; de Bruin PC; van Heerde P; van de Sandt MM; Ossenkoppele GJ; Meijer CJ
    J Clin Pathol; 1994 Jan; 47(1):33-7. PubMed ID: 8132806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.
    Bartlett NL; Smith MR; Siddiqi T; Advani RH; O'Connor OA; Sharman JP; Feldman T; Savage KJ; Shustov AR; Diefenbach CS; Oki Y; Palanca-Wessels MC; Uttarwar M; Li M; Yang J; Jacobsen ED
    Leuk Lymphoma; 2017 Jul; 58(7):1607-1616. PubMed ID: 27868471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD30 expression in non-Hodgkin's lymphoma.
    Piris M; Brown DC; Gatter KC; Mason DY
    Histopathology; 1990 Sep; 17(3):211-8. PubMed ID: 2173674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathologic characteristics and novel biomarkers of aggressive B-cell lymphomas in the nasopharynx.
    Chen PH; Yang Y; O'Malley DP; Xu ML
    Ann Diagn Pathol; 2019 Aug; 41():129-135. PubMed ID: 31247533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies.
    Fabbri A; Cencini E; Gozzetti A; Schiattone L; Bocchia M
    Anticancer Agents Med Chem; 2017; 17(7):886-895. PubMed ID: 27592544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.